Companies › Ferring Pharmaceuticals
2 active drug programs in 6 registered trials: 4 Phase 3, 2 Phase 1; Oncology, Gastroenterology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Nadofaragene Firadenovec Interferon alpha-2 exogenous gene | IFNA2 | Phase 3 | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ; Intermediate Risk Non-Muscle Invasive Bladder Cancer; Bladder Cancer; Low-grade Upper Tract Urothelial Carcinoma … | Jun 2028 |
| CLENPIQ Osmotic laxative containing sodium picosulfate, magnesium oxide, and citric acid | – | Phase 1 | Bowel Preparation | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04113382 | CLENPIQ | Phase 1 | Bowel Preparation | Gastroenterology | Dec 2027 |
| NCT06929286 | Nadofaragene Firadenovec | Phase 3 | Non-Muscle Invasive Bladder Cancer | Oncology | Apr 2028 |
| NCT06545955 | Nadofaragene Firadenovec | Phase 3 | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | Oncology | Jun 2028 |
| NCT06510374 | Nadofaragene Firadenovec | Phase 3 | Intermediate Risk Non-Muscle Invasive Bladder Cancer | Oncology | Sep 2028 |
| NCT05704244 | Nadofaragene Firadenovec | Phase 3 | Bladder Cancer | Oncology | Nov 2029 |
| NCT06668493 | Nadofaragene Firadenovec | Phase 1 | Low-grade Upper Tract Urothelial Carcinoma | Oncology | Nov 2029 |
–
Xuanzhu Biopharmaceutical Zhejiang Doer Biologics Hinova Pharmaceuticals Norroy Bioscience Onconic Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.